D Orazio & Associates Inc. Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

D Orazio & Associates Inc. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,924 shares of the biopharmaceutical company’s stock, valued at approximately $245,000.

A number of other hedge funds also recently bought and sold shares of GILD. Oppenheimer Asset Management Inc. lifted its position in Gilead Sciences by 0.5% during the third quarter. Oppenheimer Asset Management Inc. now owns 184,172 shares of the biopharmaceutical company’s stock worth $15,441,000 after buying an additional 948 shares in the last quarter. Carrera Capital Advisors raised its stake in Gilead Sciences by 23.6% during the third quarter. Carrera Capital Advisors now owns 25,546 shares of the biopharmaceutical company’s stock worth $2,142,000 after purchasing an additional 4,886 shares during the period. Aptus Capital Advisors LLC boosted its holdings in Gilead Sciences by 3.9% in the 3rd quarter. Aptus Capital Advisors LLC now owns 8,263 shares of the biopharmaceutical company’s stock valued at $693,000 after purchasing an additional 309 shares during the last quarter. Commonwealth Retirement Investments LLC grew its stake in shares of Gilead Sciences by 8.1% in the 3rd quarter. Commonwealth Retirement Investments LLC now owns 24,510 shares of the biopharmaceutical company’s stock valued at $2,055,000 after buying an additional 1,828 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in shares of Gilead Sciences by 1.9% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,023,984 shares of the biopharmaceutical company’s stock valued at $253,531,000 after buying an additional 55,841 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on GILD. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Barclays upped their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. BMO Capital Markets upped their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, ten have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $91.50.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,947 shares of company stock worth $4,968,674. 0.29% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

Shares of GILD traded down $1.57 during midday trading on Wednesday, reaching $92.78. 2,329,028 shares of the stock were exchanged, compared to its average volume of 7,036,115. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.11 and a quick ratio of 0.82. The company has a market capitalization of $115.51 billion, a price-to-earnings ratio of 1,048.33, a PEG ratio of 3.01 and a beta of 0.17. The business’s 50-day moving average price is $85.95 and its 200 day moving average price is $75.57.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.32%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is currently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.